페니트리움바이오

187660KOSDAQ자연과학 및 공학 연구개발업

54.9 / 100

Reference Date: 2026-07-24

Financial Score14.0 / 40

News Sentiment18.9 / 25

Momentum7.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 21.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Penitrium Bio operates as a Contract Research Organization (CRO), providing comprehensive clinical trial services to pharmaceutical companies and biotech ventures, leveraging AI and big data for digital clinical trial technologies. The company also conducts Phase IV clinical trials to monitor drug safety and efficacy post-market approval and develops oncology treatments through its biotech business.

Number of Employees

110people

Average Salary

72.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

11.35Industry Average 2.520.0Point

4.5x industry avg (risky)

ROE

-105.34Industry Average -32.093.5Point

3.3x industry avg (excellent)

Debt Ratio

3.59Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼17.1% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼153.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -79.0% (declining, 3yr)

Detailed News Sentiment

14 totalPositive 10Neutral 1Negative 3Average Sentiment Score 75.7

Negative
주가 급락에 조달액도 '뚝'…주주배정 증자 바이오기업 비상
페니트리움바이오의 주가 급락과 함께 주주배정 증자 자금 조달 계획이 크게 축소되어 부정적 영향이 예상됩니다.
Positive
페니트리움바이오, 미국 임상 2상 직행...속도·승인률·가치 높이는 ....
페니트리움바이오의 핵심 신약 후보물질이 미국 임상 2상에 진입함으로써 개발 속도와 성공 가능성이 높아져 긍정적인 시장 반응을 기대할 수 있다.
Positive
페니트리움바이오 "美 2상부터 시작은 정상적인 개발 절차...글로벌 사...
페니트리움바이오는 신약 개발의 정상적인 진행 과정을 강조하며 긍정적인 시장 반응을 보임.

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 4,405Won52-week high 18,67052-week low 1,388

1-month return0.0Point

1m -21.34% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

9 totalPositive 3Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-22
Neutral[기재정정]기업설명회(IR)개최2026-07-07
Neutral기업설명회(IR)개최2026-07-03
Neutral투자설명서2026-06-26
Neutral효력발생안내( 2026.6.11. 제출 증권신고서(지분증권) )2026-06-26